Dr Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, Miller School of Medicine, University of Miami, Miami, FL, U.S.A.
Sanofi, Guildford, U.K.
Br J Dermatol. 2019 Oct;181(4):761-769. doi: 10.1111/bjd.17744. Epub 2019 May 1.
Moderate-to-severe atopic dermatitis (AD) is a chronic disease characterized by intense, persistent and debilitating itch, resulting in sleep deprivation, signs of anxiety and depression, impaired quality of life and reduced productivity. The Peak Pruritus Numerical Rating Scale (NRS) was developed and validated as a single-item, patient-reported outcome (PRO) of itch severity.
To describe the content validity and psychometric assessment (test-retest reliability, construct validity, known-groups validity, sensitivity to change) of the Peak Pruritus NRS, and to derive empirically a responder definition to identify adults with a meaningful change in itch.
Content validity was assessed through in-depth patient interviews. Psychometric assessments used data from phase IIb and phase III dupilumab clinical trials and included test-retest reliability, construct validity, known-groups validity and sensitivity to change in patients with moderate-to-severe AD.
Interview participants indicated that the Peak Pruritus NRS was a relevant, clear and comprehensive assessment of itch severity. Peak Pruritus NRS scores showed large, positive correlations with existing PRO measures of itch, and weak or moderate correlations with clinician-reported measures assessing objective signs of AD. Peak Pruritus NRS score improvements were highly correlated with improvements in other itch PROs, and moderately correlated with improvements in clinician-reported measures assessing objective signs of AD. The most appropriate threshold for defining a clinically relevant, within-person response was ≥ 2-4-point change in the Peak Pruritus NRS.
The Peak Pruritus NRS is a well-defined, reliable, sensitive and valid scale for evaluating worst itch intensity in adults with moderate-to-severe AD.
中重度特应性皮炎(AD)是一种慢性疾病,其特征为剧烈、持续和使人虚弱的瘙痒,导致睡眠剥夺、焦虑和抑郁迹象、生活质量受损和生产力下降。瘙痒峰值数字评定量表(NRS)是作为一种单一项目、患者报告的结局(PRO)瘙痒严重程度而开发和验证的。
描述瘙痒峰值 NRS 的内容效度和心理测量评估(测试-重测信度、结构效度、已知群体效度、对变化的敏感性),并根据经验得出一个应答者定义,以识别瘙痒有显著变化的成年人。
内容效度通过深入的患者访谈进行评估。心理测量评估使用来自 IIb 期和 III 期度普利尤单抗临床试验的数据,包括中重度 AD 患者的测试-重测信度、结构效度、已知群体效度和对变化的敏感性。
访谈参与者表示,瘙痒峰值 NRS 是一种与瘙痒严重程度相关的、清晰且全面的评估方法。瘙痒峰值 NRS 评分与现有的瘙痒 PRO 测量方法呈显著正相关,与评估 AD 客观体征的临床医生报告测量方法呈弱或中度相关。瘙痒峰值 NRS 评分的改善与其他瘙痒 PRO 评分的改善高度相关,与评估 AD 客观体征的临床医生报告测量方法的改善中度相关。定义个体内有临床意义的反应的最合适阈值为瘙痒峰值 NRS 变化≥2-4 点。
瘙痒峰值 NRS 是一种定义明确、可靠、敏感且有效的评估中重度 AD 成人最剧烈瘙痒强度的量表。